Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
1. An isolated polypeptide consisting of the sequence of SEQ ID NO:461.
2. A fusion protein consisting of the polypeptide of claim 1 and a fusion partner selected from the group consisting of Ra12, protein D, LYTA, a HIS tag, a targeting signal capable of directing a polypeptide to the endosomal/lysosomal compartment, and a twin arginine translocation signal peptide.
3. The fusion protein of claim 2 wherein the fusion partner is a twin arginine translocation signal peptide.
4. A composition comprising the polypeptide according to claim 1 in combination with a pharmaceutically acceptable carrier or excipient.
5. A composition comprising the polypeptide according to claim 1 in combination with an immunostimulant.
6. The composition according to claim 5 wherein the immunostimulant preferentially enhances a T cell response in a human.
7. The composition according to claim 5 , wherein the immunostimulant is selected from the group consisting of 3-de-O-acylated monophosphoryl lipid A, monophosphoryl lipid A, aminoalkyl glucosaminide 4-phosphates, cytokines, microspheres, , saponin based adjuvants, and immune stimulating complex based adjuvants.
8. A fusion protein consisting of the polypeptide of claim 1 and a twin arginine translocation signal peptide.
9. A composition comprising the fusion protein of claim 8 in combination with a pharmaceutically acceptable carrier or excipient.
10. The composition of claim 9 , further comprising an immunostimulant.
11. The composition of claim 10 , where said immunostimulant preferably enhances a T cell response in a human.
12. The composition of claim 9 , further comprising monophosporyl lipid A.
13. The composition of claim 9 , further comprising 3-de-O-acylated monophosporyl lipid A.
14. The composition of claim 9 , further comprising a saponin.